BioViva Sciences Inc

  • Home
  • BioViva Sciences Inc

BioViva Sciences Inc BioViva is a gene therapy company that treats aging as a disease.
(1)

Well this is the problem will all in thinking. Decades of lost time.
28/04/2026

Well this is the problem will all in thinking. Decades of lost time.

Researchers have found that the absolute effects of anti-amyloid drugs on cognitive decline and dementia severity were absent or trivial

Researchers showed that editing a small number of blood stem cells can reprogram the immune system to continuously produ...
28/04/2026

Researchers showed that editing a small number of blood stem cells can reprogram the immune system to continuously produce therapeutic proteins, including powerful antibodies that are normally hard to generate. In mice, this approach created long-lasting, boostable protection against infections and could potentially be adapted to treat diseases ranging from HIV to genetic disorders and cancer.

An innovative gene-editing strategy could establish a new way for the body to manufacture therapeutic proteins—including certain kinds of highly potent antibodies that are naturally difficult to produce—by reprogramming the immune system itself.

Lower levels of the anti-aging protein Klotho after surgery were strongly linked to higher inflammation and worse cognit...
26/04/2026

Lower levels of the anti-aging protein Klotho after surgery were strongly linked to higher inflammation and worse cognitive function in patients with postoperative cognitive dysfunction (POCD). This suggests Klotho could be a useful early biomarker—and possibly a treatment target—for predicting and improving cognitive outcomes after surgery.

Investigating the association between serum Klotho levels and postoperative cognitive dysfunction, and relationships with inflammation and cognitive outcomes.

The DNA Fix for AgingEveryone’s DNA keeps mutating. Could correcting those errors lead to longevity?
25/04/2026

The DNA Fix for Aging
Everyone’s DNA keeps mutating. Could correcting those errors lead to longevity?

Everyone’s DNA keeps mutating. Could correcting those errors lead to longevity?

Researchers analyzed ~250,000 pancreatic islet cells and found that in type 2 diabetes, about 25% of insulin-producing b...
24/04/2026

Researchers analyzed ~250,000 pancreatic islet cells and found that in type 2 diabetes, about 25% of insulin-producing beta cells are lost and many of the remaining ones become aged and dysfunctional. They identified dozens of genes—along with pathways like vitamin A metabolism—that likely drive beta cell death, highlighting new potential targets for treatment.

Dozens of unexpected genes are strongly linked to type 2 diabetes, new research from The Jackson Laboratory (JAX) shows. The findings, based on a new genomic atlas of pancreatic cells from non-diabetic, prediabetic, and diabetic people, suggest the disease depends on expression of genes key to cell....

24/04/2026

The study validated FGF21-a liver-derived hormone currently in clinical trials for fatty liver disease “as a dual-action therapeutic that both curbs harmful drinking behaviors and protects against alcohol-related liver injury

His team was the first to demonstrate the effectiveness of targeting the SMN gene in models of spinal muscular atrophy, ...
23/04/2026

His team was the first to demonstrate the effectiveness of targeting the SMN gene in models of spinal muscular atrophy, helping pave the way for clinical trials and the approval of gene-based treatments.

Moroccan researcher Mimoun Azzouz has received the “Outstanding Achievement Award” from the British Society for Gene and Cell Therapy, recognizing his contributions to gene therapy research and scientific training.

“We have four drug candidates for patients with an ultra-rare disease with Polish origins, the PUS3 syndrome; one of the...
22/04/2026

“We have four drug candidates for patients with an ultra-rare disease with Polish origins, the PUS3 syndrome; one of these candidates will be used in practice,” Lisowski said.

Polish researchers have developed four gene therapy candidates for patients with PUS3 syndrome, an ultra-rare genetic disorder believed to have Polish origins, with one candidate expected to be selected for clinical use, according to geneticist Professor Leszek Lisowski.

The glioblastoma tumor immune microenvironment (TIME) is an immunosuppressive barrier to therapy that encumbers glioblas...
20/04/2026

The glioblastoma tumor immune microenvironment (TIME) is an immunosuppressive barrier to therapy that encumbers glioblastoma responses to immune checkpoint inhibition (ICI).

Abstract. The glioblastoma tumor immune microenvironment (TIME) is an immunosuppressive barrier to therapy that encumbers glioblastoma responses to immune checkpoint inhibition (ICI). Immunosuppressive cytokines, pro-tumor macrophages and myeloid cells, and exhausted T-cells are all hallmarks of the...

18/04/2026

...Follistatin protein, which plays a key role both in inhibiting tumors and promoting muscle tissue growth.
https://pulse.ly/ow2va0i0lk

Address


Alerts

Be the first to know and let us send you an email when BioViva Sciences Inc posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Practice

Send a message to BioViva Sciences Inc:

  • Want your practice to be the top-listed Clinic?

Share